Article Dans Une Revue Diabetologia Année : 2020

Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort

B. Gellen
  • Fonction : Auteur
N. Thorin-Trescases
  • Fonction : Auteur
E. Thorin
  • Fonction : Auteur
E. Gand
  • Fonction : Auteur
P. Sosner
Vincent Rigalleau
D. Montaigne
  • Fonction : Auteur
V. Javaugue
  • Fonction : Auteur
Y. Pucheu
  • Fonction : Auteur
P. Gatault
  • Fonction : Auteur
X. Piguel
  • Fonction : Auteur
S. Hadjadj
  • Fonction : Auteur
P. J. Saulnier
S. Brishoual
  • Fonction : Auteur
  • PersonId : 1544465

Résumé

Aims/hypothesis: Tenascin-C (TN-C) is an extracellular matrix glycoprotein highly expressed in inflammatory and cardiovascular (CV) diseases. Serum TN-C has not yet been specifically studied in individuals with type 2 diabetes, a condition associated with chronic low-grade inflammation and increased CV disease risk. In this study, we hypothesised that elevated serum TN-C at enrolment in participants with type 2 diabetes would be associated with increased risk of death and major adverse CV events (MACE) during follow-up. Methods: We used a prospective, monocentric cohort of consecutive type 2 diabetes participants (the SURDIAGENE [SUivi Rénal, DIAbète de type 2 et GENEtique] cohort) with all-cause death as a primary endpoint and MACE (CV death, non-fatal myocardial infarction or stroke) as a secondary endpoint. We used a proportional hazard model after adjustment for traditional risk factors and the relative integrated discrimination improvement (rIDI) to assess the incremental predictive value of TN-C for these risk factors. Results: We monitored 1321 individuals (58% men, mean age 64 ± 11 years) for a median of 89 months. During follow-up, 442 individuals died and 497 had MACE. Multivariate Cox analysis showed that serum TN-C concentrations were associated with an increased risk of death (HR per 1 SD: 1.27 [95% CI 1.17, 1.38]; p < 0.0001) and MACE (HR per 1 SD: 1.23 [95% CI 1.13, 1.34]; p < 0.0001). Using TN-C concentrations on top of traditional risk factors, prediction of the risk of all-cause death (rIDI: 8.2%; p = 0.0006) and MACE (rIDI: 6.7%; p = 0.0014) improved significantly, but modestly. Conclusions/interpretation: In individuals with type 2 diabetes, increased serum TN-C concentrations were independently associated with death and MACE. Therefore, including TN-C as a prognostic biomarker could improve risk stratification in these individuals.

Mots clés

Dates et versions

hal-03121403 , version 1 (26-01-2021)

Identifiants

Citer

B. Gellen, N. Thorin-Trescases, E. Thorin, E. Gand, P. Sosner, et al.. Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort. Diabetologia, In press, 63 (5), pp.915-923. ⟨10.1007/s00125-020-05108-5⟩. ⟨hal-03121403⟩
45 Consultations
0 Téléchargements

Altmetric

Partager

  • More